Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA

INTRODUCTION: Biologics are a standard therapy for patients with moderate-to-severe psoriasis, yet treatment persistence is essential to achieve disease control. Compared with other biologics, ustekinumab has been associated with lower rates of discontinuation and better adherence among patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilon, Dominic, Fitzgerald, Timothy, Zhdanava, Maryia, Teeple, Amanda, Morrison, Laura, Shah, Aditi, Lefebvre, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021356/
https://www.ncbi.nlm.nih.gov/pubmed/35305255
http://dx.doi.org/10.1007/s13555-022-00707-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021356/
https://www.ncbi.nlm.nih.gov/pubmed/35305255
http://dx.doi.org/10.1007/s13555-022-00707-z

Ejemplares similares